Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1056763 | 1.00 | KLK5 (0.45) | KLK5CTSSACETACR1MAPT | |
| SCHEMBL13316851 | 0.89 | CTSS (0.40) | CTSSACEMAPTALDH1A1AAK1 | |
| SCHEMBL1061604 | 0.89 | KLK5 (0.48) | KLK5CTSSACETACR1MAPT | |
| SCHEMBL1055858 | 0.89 | ACE (0.49) | CTSSACECTSLCTSBCTSK | |
| SCHEMBL1061605 | 0.89 | KLK5 (0.48) | KLK5CTSSACETACR1MAPT | |
| SCHEMBL1055857 | 0.89 | ACE (0.49) | CTSSACECTSLCTSBCTSK | |
| SCHEMBL28888255 | 0.88 | KLK5 (0.43) | KLK5CTSSACETACR1MAPT | |
| SCHEMBL28888254 | 0.88 | KLK5 (0.43) | KLK5CTSSACETACR1MAPT | |
| SCHEMBL12600964 | 0.87 | ACE (0.42) | CTSSACEMAPTALDH1A1AAK1 | |
| SCHEMBL23375900 | 0.87 | KLK5 (0.44) | KLK5CTSSACETACR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111377832-A | Novel method for preparing irudoline intermediate | 江苏联昇化学有限公司 | 2020-07-07 | — | — | CN | claimed |
| CN-108026032-B | Method for producing optically active 4-carbamoyl-2, 6-dimethylphenylalanine derivative | 株式会社钟化 | 2020-09-29 | — | — | CN | disclosed |
| CN-111377832-A | Novel method for preparing irudoline intermediate | 江苏联昇化学有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-111377832-A | Novel method for preparing irudoline intermediate | 江苏联昇化学有限公司 | 2020-07-07 | — | — | CN | disclosed |
| EP-3112352-B1 | OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-21 | — | — | EP | disclosed |
| US-20180325870-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2018-11-15 | — | — | US | disclosed |
| EP-2362868-B1 | PROCESS FOR THE PREPARATION OF PROTECTED L-ALANINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-20 | — | — | EP | disclosed |
| US-9700542-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-11 | — | — | US | disclosed |
| US-9700542-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-11 | — | — | US | disclosed |
| EP-3112352-A1 | OPIOID RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2017-01-04 | — | — | EP | disclosed |
| WO-2006099060-A2 | PROCESS FOR THE PREPARATION OF OPIOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006098982-A1 | PROCESS FOR THE PREPARATION OF OPIOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211863-A1 | Process for the preparation of opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-21 | — | — | US | disclosed |
| US-20060211861-A1 | Process for the preparation of opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-21 | — | — | US | disclosed |
| US-7041681-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-09 | — | — | US | disclosed |
| US-20060030558-A1 | Novel compounds as opioid receptor modulators | BRESLIN HENRY J | 2006-02-09 | — | — | US | disclosed |
| WO-2005090315-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N. V. (BE) | 2005-09-29 | — | — | WO | disclosed |
| US-20050203143-A1 | use as pain relievers, gastrointestinal disorders such as inflammatory bowel disease; compounds are aminoacetamide derivatives substituted with an imidazole; 5-(([2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino)-methyl)-2-methoxy-benzoic acid for example | JANSSEN PHARMACEUTICA, N. V. (BE) | 2005-09-15 | — | — | US | disclosed |
| US-20050187252-A1 | 2-Amino-3-(4-hydroxy-phenyl)-1-[2-(5-phenyl-oxazol-2-yl)-piperidin-1-yl]-propan-1-one; pain and gastrointestinal disorders | BRESLIN HENRY J (US) | 2005-08-25 | — | — | US | disclosed |
| US-20040010014-A1 | Novel compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203143-A1 | use as pain relievers, gastrointestinal disorders such as inflammatory bowel disease; compounds are aminoacetamide derivatives substituted with an imidazole; 5-(([2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino)-methyl)-2-methoxy-benzoic acid for example | OPRK1, OPRM1, OPRL1 | KLK5 3907/4885CTSS 3659/4885ACE 2301/4885 |
| US-20060030558-A1 | Novel compounds as opioid receptor modulators | OPRL1, OPRK1, OPRM1 | KLK5 3720/4885CTSS 3517/4885ACE 3541/4885 |
| US-20060211861-A1 | Process for the preparation of opioid modulators | OPRM1, OPRK1, OPRL1 | KLK5 2264/4885CTSS 2017/4885ACE 2759/4885 |
| US-20050187252-A1 | 2-Amino-3-(4-hydroxy-phenyl)-1-[2-(5-phenyl-oxazol-2-yl)-piperidin-1-yl]-propan-1-one; pain and gastrointestinal disorders | OPRL1, OPRK1, OPRD1 | KLK5 3666/4885CTSS 4047/4885ACE 3236/4885 |
| US-20040010014-A1 | Novel compounds as opioid receptor modulators | OPRL1, OPRK1, OPRM1 | KLK5 3720/4885CTSS 3517/4885ACE 3541/4885 |
| US-20180325870-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | KLK5 2436/4885CTSS 3591/4885ACE 2723/4885 |
| US-20060211863-A1 | Process for the preparation of opioid modulators | OPRM1, OPRK1, OPRL1 | KLK5 2264/4885CTSS 2017/4885ACE 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.